Share
Optimum Perspectives
Interviews with industry leaders of the healthcare sector.
Latest episode
40. New approaches to treating kidney disease
25:51||Ep. 40Dialysis and transplantation have transformed the lives of people with serious kidney disease. But that does not mean it is “job done”. Individuals who need dialysis have significantly reduced life expectancy, especially if they must remain on it for a long time, while there is a shortage of donor kidneys – and transplantation carries its own problems. In this latest Optimum Perspectives podcast, three experts who are all developing new treatments for various aspects of kidney disease, share their thoughts. Stephen Adams hosts the episode, which features Renée Aguiar-Lucander, CEO of Hansa Biopharma; Krishna Polu, CEO of R1 Therapeutics; and Thomas Kledal, CEO of Synklino.
More episodes
View all episodes
39. How sleep architecture shapes brain health: new frontiers in Alzheimer’s research
19:58||Ep. 39On World Sleep Day 2026, Optimum is marking the occasion with a brand-new podcast episode featuring Magnus Ivarsson, CSO of AstronauTx and Prof. Liz Coulthard from the University of Bristol. Did you know getting enough high quality sleep could help protect against developing neurological diseases including Alzheimer’s? This episode delves into the groundbreaking research our guests are doing in the intersection between sleep and neurodegeneration.38. Closing the gap on rare diseases in 2026
18:44||Ep. 38Ahead of Rare Disease Day 2026, Optimum is marking the occasion with a brand-new podcast episode featuring Hans Schambye, CEO of BOOST Pharma, Jean-Marie Cuillerot, CMO of Kainova Therapeutics, and Josep Prous, Co‑founder & CSO of CONNECTA.This episode delves into the critical gaps in therapeutic options for the more than 300 million people living with rare diseases worldwide and explores why this field is rapidly gaining attention from both researchers and investors.Our guests also share insights into their life‑changing work across brittle bone disease, oncology, and fragile X syndrome, highlighting the breakthroughs that are bringing new hope to patients and families.37. Why who funds science matters
26:47||Ep. 37🎙️On this International Day of Women and Girls in Science, we’re shifting the spotlight to the women funding the future of innovation. This celebratory episode of the #OptimumPerspectivesPodcast explores how female venture capitalists are shaping the future of science, technology, and innovation, and why who funds science matters almost as much as who does the science. Listen to the full episode featuring Victoria Taylor of Medicxi, Bonnie van Wilgenburg of Monograph Capital and Noga Yerushalmi of M Ventures.#IDWGIS2026 #WomeninSTEM36. Tackling the threat of AMR
31:21||Ep. 36Antimicrobial Resistance (AMR) is an increasingly wide-scale problem. Not contained by borders, and with the ability to turn minor infections into life threatening conditions, it is an issue that experts argue must be addressed in the present, not the future. Hear from Jennifer Schneider of Centauri Therapeutics, Franz-Werner Haas of LimmaTech Biologics and Neil Murray of ReNewVax on their unique approaches to tackling the threat of AMR, in the latest episode of the Optimum Perspectives Podcast.35. The ups and downs of ADCs – where to now?
29:44||Ep. 35Just in time for World ADC San Diego 2025 - a brand new episode of the Optimum Perspectives Podcast is live! Join Francois Bertelli of DISCO Pharmaceuticals, Stefano Gulla of Kling Biotherapeutics, and Michael Bauer of Novo Holdings, as they dive into the hot topic: ‘The ups and downs of ADCs – where to now?’ Expect sharp insights and forward-looking perspectives on the evolving ADC landscape. Listen to the full episode here.34. Q&A with CSO Caroline Benn discussing LoQus23's unique approach to Huntington’s disease
23:15||Ep. 34The latest episode of Optimum Perspectives Podcast has just dropped, featuring LoQus23 Therapeutics’ Chief Scientific Officer and founder Caroline Benn! Listen as Caroline details the devastating effects of Huntington’s Disease on patients and families, her personal motivations for working in this therapeutic area, as well as LoQus23’s unique approach to battling the disease through their innovative small molecule approach.